Many patients with chronic, painful illness find conventional treatments unsatisfactory; adverse reactions or inadequate efficacy are common problems and patients may look for alternative forms of treatment. Herbal remedies have been popular since antiquity' and have the attraction, at first glance, of being relatively inexpensive, 'natural', and free of adverse effects. In the late 1970s newspaper reports of the efficacy of feverfew (Tanacetum parthenium) provoked a resurgence of interest in this herb, alleged by the folklore to be beneficial in psoriasis, migraine, and arthritis. More recently, in vitro demonstration of inhibition of polymorphonuclear secretory activity by extract of feverfew provided a mechanism to support such anecdotal claims,2 and two clinical trials have shown feverfew to be beneficial in migraine.3 4 We therefore undertook a prospective double blind, placebo controlled trial to investigate the possible clinical, anti-inflammatory effect of feverfew in patients with arthritis. Rheumatoid arthritis (RA) was chosen because of its recognised inflammatory component. 
Patients and methods
The study was approved by the local ethical committee. Female patients under the age of 65 with classical or definite RA attending the rheumatology unit at the City Hospital, Nottingham were invited to participate. Each had inadequately controlled inflammatory joint symptoms and were being considered for a change of non-steroidal anti-inflammatory drug treatment or commencement of 'second line' treatment, or both. Forty one patients entered the study. Each was randomly allocated to receive either feverfew or matching placebo in identical red gelatin capsules taken once daily for six weeks. Capsules were prepared and contained either 70-86 mg (mean 76 mg) dried, powdered feverfew leaf (equivalent to 2-3 iLmol parthenolide) or placebo (identically treated cabbage). One capsule of feverfew thus corresponded to two medium sized leaves.
Patients were advised to store capsules in a domestic refrigerator (4°C). Current non-steroidal antiinflammatory and analgesic treatment was maintained but not altered during the trial. Patients These properties, in conjunction with the folklore, prompted us to study the clinical effect of feverfew in patients with RA. We primarily sought symptomatic and functional benefit, rather than second line effect, within the time scale reported in the folklore (improvement usually occurring within one to three weeks of regular usage9 l()). Standard laboratory investigations were additionally performed to assess comparability between placebo and treatment groups, and to detect any in vivo anti-inflammatory effects that might be expected from the dramatic, rapidly acting in vitro properties.2 7 This double blind trial, however, showed no additional benefit from feverfew during the six week period. Although 'significant' changes occurred in two of the factors examined (one in favour, one against feverfew), this was no more than expected by chance in a study examining 21 variables. Although it is possible that we gave an inadequate dose (two reports suggest up to 100 mg"' to 125 mg") daily for efficacy), most authors emphasise the quality rather than quantity of herb.9 One to two leaves daily is the usual dose discussed in folklore,l and an equivalent dose, as used in this study, has been reported to be effective in migraine.4 It is said that concomitant non-steroidal anti-inflammatory drugs or steroid may reduce the efficacy offeverfew. "'
In practice, however, many patients use feverfew as a supplement to their conventional drug treatment, and it was considered unethical to withdraw antiinflammatory treatment completely for the purpose of this study. Indeed, the high incidence of intraarticular steroid requirement at three weeks reflects the poor disease control in these selected patients; similar injection requirements in both groups argue against such treatment being a confounding factor in the results.
Although feverfew extract is active in vitro and the preparation of feverfew used has been shown to be effective in migraine,4 we have no direct evidence that it was absorbed from the gut in our patients with RA. Although not suggested by folklore, a slow acting, second line effect from feverfew cannot be excluded by this six week study. Equally, it does not exclude possible benefit for osteoarthritis and soft tissue lesions, for which self treatment with feverfew is probably most common.
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